Shet Anita, Kaplan Edward
Department of Pediatrics, WHO, Collaborating Center for Reference and Research on Streptococci, University of Minnesota Medical School, Minneapolis 55455, USA.
Indian J Pediatr. 2004 Jan;71(1):41-8. doi: 10.1007/BF02725655.
Group A streptococcus-associated disease and sequelae continue to have devastating effects on public health and national economy as they mainly affect children and young adults. There is an urgent need for wider application of methods of primary prevention, in the form of optimal diagnosis and management of the simple group A streptococcal sore throat. This review article briefly summarizes the burden of streptococcal disease in India, and discusses treatment options standardized by the World Health Organization. Penicillin continues to remain the drug of choice for treating group A streptococcal pharyngitis and for prevention of acute rheumatic fever in non-allergic patients. Also discussed in this review are contemporary thoughts on streptococcal "carriers", recurrent infections, antibiotic treatment "failures" and emergence of drug resistance among group A streptococci.
A组链球菌相关疾病及其后遗症继续对公众健康和国民经济产生毁灭性影响，因为它们主要影响儿童和年轻人。迫切需要更广泛地应用一级预防方法，即对单纯性A组链球菌性咽喉炎进行最佳诊断和管理。这篇综述文章简要总结了印度链球菌病的负担，并讨论了世界卫生组织标准化的治疗方案。青霉素仍然是治疗A组链球菌性咽炎以及预防非过敏患者急性风湿热的首选药物。本综述还讨论了关于链球菌“携带者”、复发性感染、抗生素治疗“失败”以及A组链球菌耐药性出现的当代观点。
